Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years, has been demonstrated to slow the decline in the loss of physical function in ALS patients by 33 percent in its clinical trial. Please contact the Lois Insolia ALS Clinic at Northwestern Medicine and consult your physician to find out if Radicava is right for you.
To read the full press release and obtain other informative Radicava resources, visit our Approved Treatments page.
